Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer.

Department of Surgery II, Kumamoto University Medical School, Honjo 1-1-1, Kumamoto 860-8556, Japan.
International Journal of Oncology (Impact Factor: 2.66). 12/2004; 25(5):1303-9. DOI: 10.3892/ijo.25.5.1303
Source: PubMed

ABSTRACT In our previous investigations, mitogen-activated protein kinase kinase 2 (MEK2)/extracellular signal-regulated kinase 2 (ERK2) signaling pathway was found to be correlated with the cell dissociation induced by dissociation factor (DF) in pancreatic cancer cells. In this study, the expressions of epidermal growth factor receptor (EGFR), phosphorylated EGFR (p-EGFR), and its downstream kinases MEK1/2 and ERK1/2, were analyzed to clarify the regulatory mechanism of cell dissociation in pancreatic cancer cells. Two hamster (PC-1.0 and PC-1) and two human (AsPC-1 and Capan-2) pancreatic cancer cell lines were used. Immunocytochemical study was performed using anti-EGFR, p-EGFR, phosphorylated MEK1/2 (p-MEK1/2), and phosphorylated ERK1/2 (p-ERK1/2) antibodies. DF-treatment markedly induced the expressions of EGFR, p-EGFR, p-MEK1/2, p-ERK1/2, as well as the dissociation of cell colonies in PC-1 and Capan-2 cells. In contrast, AG1478 (an EGFR inhibitor) treatment significantly induced the cell aggregation in PC-1.0 and AsPC-1 cells which usually grew as single cells, but strongly suppressed the expressions of EGFR, p-EGFR, p-MEK1/2, and p-ERK1/2. These observations demonstrate that activation of EGFR is closely involved in cell dissociation in pancreatic cancer through activating MEK/ERK signaling pathway.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal Growth Factor Receptor (EGFR or HER1) is considered a tumor associated antigen. HER1 is overexpressed in many human epithelial tumors and involved in crucial cellular functions for tumor development. For this reason HER1 is considered a good target for cancer immunotherapy and some passive agents are being evaluated in clinical trials. However, HER1-based active immunotherapy has not been clinically explored. To develop an active immunotherapy approach based on HER1 for the treatment of HER1+ cancer patients, we cloned and expressed in mammalian cells the HER1 extracellular domain protein (HER1-ECD), which was specifically recognized by an anti- EGFR monoclonal antibody. HER1-ECD was purified by affinity chromatography and adjuvated in Very Small Size Proteoliposomes (VSSP) or Complete Freund adjuvant to immunize C57BL/6 mice. Immunization elicited specific humoral and cellular immune response. The polyclonal antibodies induced by immunization recognized the full length HER1 on the surface of a lung tumor cell line. These results suggest that HER1-ECD could be an appropriated antigen to induce specific immune response in patients with HER1+ tumors.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The acquisition of a cancerous phenotype by epithelial cells involves the disruption of intercellular adhesions. The reorganization of the E-cadherin/beta-catenin complex in adherens junctions during cell transformation is widely recognized. Instead the implication of tight junctions (TJs) in this process is starting to be unraveled. The aim of this article is to review the role of TJ proteins in cell proliferation and cancer.
    Progress in Histochemistry and Cytochemistry 02/2007; 42(1):1-57. · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Long-term survival of surgically resectable pancreatic cancer patients is uncommon. The epidermal growth factor receptor (EGFR) and the phosphoinositol-3-kinase pathways are often activated in pancreatic cancer, and an understanding of their role in resected cases may help refine adjuvant therapy. We investigated the expression of EGFR, Erk, Akt, and their phosphoforms (p-) in pancreatectomy specimens and correlated these with survival. Thirty-nine consecutive surgically resected pancreatic adenocarcinoma cases were included. Immunohistochemical staining of paraffin-embedded blocks was performed by using monoclonal antibodies against EGFR, Erk, p-Erk, Akt, and p-Akt. A standard immunoperoxidase technique was used to detect the avidin-biotin peroxidase complex. Immunostaining was visually scored with the histoscore method by two surgical pathologists. Patient characteristics were as follows: 17 men and 22 women; median age, 66 years; and American Joint Committee on Cancer stage I, 5 patients; stage II, 4 patients; stage III, 27 patients; and stage IV, 3 patients. The tumor was World Health Organization grade 1 in 4, grade 2 in 17, and grade 3 in 18 cases. Adjuvant therapies were chemotherapy (n = 6), radiotherapy (n = 1), and chemoradiotherapy (n = 17). Immunohistochemistry revealed positive expression of EGFR in 30.8%, Erk in 92.3%, p-Erk in 45.9%, Akt in 71.8%, and p-Akt in 20.5% of cases. On univariate analyses, tumor grade (P = .0098), p-Akt (P = .0003), and p-Erk (P = .0052) expression correlated with survival. On multivariate analyses, age (P = .0002; hazard ratio [HR], 1.8), grade (P = .00318; HR, 3.0), Akt (P = .0433; HR, .4), p-Akt (P = .0002; HR, .2), and p-Erk (P = .0003; HR, 3.5) expression correlated significantly with survival. p-Erk and p-Akt expression may have prognostic and therapeutic implications in pancreatic cancer.
    Annals of Surgical Oncology 08/2006; 13(7):933-9. · 4.12 Impact Factor